Table of Contents
The global cancer immunotherapies market reached $30.8 billion in 2012. This market is expected to grow to nearly $34.3 billion in 2013 and $67.9 billion in 2018 with a compound annual growth rate (CAGR) of 14.7% over the five-year period, 2013 to 2018.
This report provides:
An overview of the global market for cancer immunotherapies
Analyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs through 2018.
Analyses of factors influencing market demand such as clinical guidelines, demographic changes, and market saturation
Technological discussion including the current state, newly issued patents, and pending applications
Profiles of leading companies in the industry.
STUDY GOALS AND OBJECTIVES
This report, PHM129A Cancer Immunology and Oncolytic Virology: Technologies and Global Markets provides an overview of the current and potential global market for cancer immunotherapy and virology. The report provides comprehensive information on a number of the most common cancers, highlighting global incidence and prevalence. It identifies the need for more effective drugs for treatment of these diseases. The key objective is to present a comprehensive analysis of the current state of cancer immunotherapy and where this field is going. A second objective is to examine the current state of oncolytic virology and where this nascent field appears to be heading. Important trends in each field, clinical trials and results, new developments and sales forecasts for cancer immunotherapy from 2011 through 2018 are provided in this report. In addition, sales forecasts are presented for oncolytic virology covering the years 2011 through 2023. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the cancer market. The report also addresses opportunities for future players.
REASONS FOR DOING THE STUDY
This study was conducted to provide detailed information regarding the new area of immunology-based treatment options for cancer. There is an increasing need for new and innovative drugs. This young industry is experiencing tremendous growth. Many diseases discussed in this report are global issues, and a need exists for newer, more efficacious treatment strategies. This study looks at the latest types of treatment strategies based on immunology, as well as the new field of oncolytic virotherapy, a field still in its infancy showing immense promise for the clinical management of cancer.This BCC Research market research report will increase the reader’s awareness of current and emerging drugs and technologies for many cancers.
SCOPE OF REPORT
The scope of this study entails the current immunology therapeutics markets for several of the most common cancers. The sectors covered are colony stimulating factors (CSFs), interferon alfa and gamma products, interleukin products and therapeutic monoclonal antibodies, including antibody conjugates, cancer vaccines and other cancer treatment immunology products. Vaccines against HPV and hepatitis B are included; while such vaccines act only indirectly against cancer, they do serve to protect against the disease. Also covered is oncolytic virology, so new that its market tables have been presented separately from the immunotherapy tables. The report also includes discussion of the regulatory environment, current and developing technologies, cancer incidence, market projections and market share, along with latest trends and clinical trials.
This report is an exhaustive study on the global oncolytic immunotherapy and virology market, with important statistics and analysis on existing drugs, drug candidates in clinical testing, latest trends, market structure, market size, key drug segments and trends in technology. This study contributes to the areas of market growth in oncolytic immunotherapy strategies for several of the most common cancers, and does so from the point of view of manufacturers, product suppliers, healthcare providers, and consumers of oncology products and services. This study will be of interest largely to the pharmaceutical and biotechnology industries, as well as clinics, hospitals and research institutes. This report may also prove crucial for investment firms in the sector. This report shows current trends in oncolytic immunotherapy and virology, new developments and revenue prospects for these areas. The report provides market data for 2011 to 2018 for oncolytic immunotherapy, and 2011 to 2023 for cancer virology. It also covers commercial prospects and the likely revenues in both oncolytic immunotherapy and virology.
A number of companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products, such as the pharmaceutical and biotechnical industries and research institutes. Data were gathered from various industry sources. BCC Research spoke with officials within the industry and consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected ...
Use this report to: - Analyze the global prostate cancer market, with important statistics and analysis on existing drugs, and diagnostic technologies. - Receive information on regulatory environment, ...
MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts Summary Companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows ...